You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

carfilzomib

Showing 1 - 25 of 133
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Beverly Hills, California
    Beverly Hills Cancer Center
Dec 21, 2022

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Carfilzomib in Patients With Multiple Myeloma

Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Odense, Denmark
    Odense University Hospital
Dec 20, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Mar 24, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Not yet recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Mar 24, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022

Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)

Completed
Has Results
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
Dec 3, 2021

Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 5, 2021

Neuroendocrine Cancer Trial in United States (Carfilzomib)

Completed
Has Results
  • Neuroendocrine Cancer
  • Carfilzomib
  • Denver, Colorado
  • +9 more
Jun 7, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
Nov 25, 2021

Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +3 more
  • Boston, Massachusetts
  • +2 more
Oct 28, 2021

Myeloma, Multiple Myeloma Trial in Chicago (Daratumumab, Carfilzomib, Lenalidomide)

Recruiting
  • Myeloma
  • Multiple Myeloma
  • Chicago, Illinois
    The University of Chicago
Sep 15, 2021

Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)

Recruiting
  • Multiple Myeloma
  • Selinexor 60 MG
  • +6 more
  • Washington, District of Columbia
  • +1 more
Feb 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Aug 8, 2022

Refractory Multiple Myeloma Trial in United States (selinexor, carfilzomib, dexamethasone)

Recruiting
  • Refractory Multiple Myeloma
  • Scottsdale, Arizona
  • +4 more
Apr 1, 2022

Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Nov 18, 2021

Hodgkin Disease, Lymphoma, Non-hodgkin Trial in New York (Carfilzomib, TGR-1202)

Terminated
Has Results
  • Hodgkin Disease
  • Lymphoma, Non-hodgkin
  • New York, New York
    Columbia University Irving Medical Center - Center for Lymphoid
Jun 28, 2021

Smouldering Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Lenalidomide)

Recruiting
  • Smouldering Myeloma
  • Carfilzomib
  • +2 more
  • Brno, Czechia
  • +15 more
Mar 22, 2022

Multiple Myeloma Trial in Sweden, United States (Bortezomib, Dexamethasone, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Miami, Florida
  • +8 more
Nov 23, 2021

MULTIPLE MYELOMA (MM) Trial in Rionero in Vulture (Carfilzomib, Cyclophosphamide, Lenalidomide)

Active, not recruiting
  • MULTIPLE MYELOMA (MM)
  • Carfilzomib
  • +3 more
  • Rionero in Vulture, Italy
    IRCCS--CROB --CROB di Rionero in di Rionero in Vulture
Apr 28, 2021

Multiple Myeloma Trial in Canada, United States (Pomalidomide, Carfilzomib, dexamethasone)

Recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +4 more
Jan 7, 2022